Silas Inman

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Patients with grade 2 IDH-mutant glioma (a type of brain cancer) experienced a 61% reduced risk of progression or desk when treated with vorasidenib (AG-881) compared with placebo, according to results from the phase 3 INDIGO clinical trial, presented at the 2023 ASCO Annual Meeting and published in the New England Journal of Medicine. Progression-free survival (time from treatment until disease progression) with vorasidenib was 27.7 months compared with 11.1 months for those treated with pla…

Adding Keytruda (pembrolizumab) to pre-surgical chemotherapy and then again after surgery led to improvements in outcomes for patients with early-stage non-small cell lung cancer (NSCLC), according to findings from the phase 3 KEYNOTE-671 study presented at the 2023 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine. In particular, this Keytruda regimen improved event-free survival, which is the time a patient lives without complications from the disease,…

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.